 Home > Active Ingredient News > Antitumor Therapy > The FDA approved the Monjuvi (tafasitamab-cxix) joint lying to treat relapse diffuse large B-cell lymphoma.

The FDA approved the Monjuvi (tafasitamab-cxix) joint lying to treat relapse diffuse large B-cell lymphoma.

 Last Update: 2020-08-06
 Source: Internet
 Author: User

Tags

pharmaceutical companies michigan

united states pharmacopeia

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pharmaceutical companies MorphoSys and Incyte announced today that the U.S. Food and Drug Administration (FDA) has approved a combination of Monjuvi ® (tafasitamab-cxix) to treat patients with recurrent or refractable diffuse large B-cell lymphoma (DLBCL) that are not suitable for autologous stem cell transplantation (ASCT).
Tafasitamab-cxix is a monoclonal antibody of humanized target CD19, which has been approved by the FDA.
DLBCL is the most common non-Hodgkin lymphoma in adults worldwide, characterized by a rapid increase in the number of malignant B cells in the lymph nodes, spleen, liver, bone marrow or other organs.
DLBCL is an aggressive disease, and about one-third of patients are ineffective with initial treatment.
in the United States, about 10,000 people are diagnosed each year with recurrent or refractive DLBCL.
, depending on their genetic activity, DLBL can be divided into three main subtypes: activated B-cell lymphoma (ABC-DLBCL), biofirst B cell lymphoma (GCB-DLBCL) and primary-cell lymphoma (PMBL). "The FDA approves Monjuvi's combination with Lenadoamine to help address the urgent medical needs of patients with recurrent or refractory DLBCL in the United States," said Herv? Hoppenot, CEO of
Incyte.
in Inccyte, we are committed to improving patient care."
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.